133 related articles for article (PubMed ID: 16502348)
1. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs.
Rephaeli A; Entin-Meer M; Angel D; Tarasenko N; Gruss-Fischer T; Bruachman I; Phillips DR; Cutts SM; Haas-Kogan D; Nudelman A
Invest New Drugs; 2006 Sep; 24(5):383-92. PubMed ID: 16502348
[TBL] [Abstract][Full Text] [Related]
2. The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
Nudelman A; Levovich I; Cutts SM; Phillips DR; Rephaeli A
J Med Chem; 2005 Feb; 48(4):1042-54. PubMed ID: 15715472
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer.
Rephaeli A; Blank-Porat D; Tarasenko N; Entin-Meer M; Levovich I; Cutts SM; Phillips DR; Malik Z; Nudelman A
Int J Cancer; 2005 Aug; 116(2):226-35. PubMed ID: 15800932
[TBL] [Abstract][Full Text] [Related]
4. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
5. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Tarasenko N; Nudelman A; Rozic G; Cutts SM; Rephaeli A
Invest New Drugs; 2017 Aug; 35(4):412-426. PubMed ID: 28315153
[TBL] [Abstract][Full Text] [Related]
6. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex).
Tarasenko N; Nudelman A; Tarasenko I; Entin-Meer M; Hass-Kogan D; Inbal A; Rephaeli A
Clin Exp Metastasis; 2008; 25(7):703-16. PubMed ID: 18506586
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines.
Engel D; Nudelman A; Levovich I; Gruss-Fischer T; Entin-Meer M; Phillips DR; Cutts SM; Rephaeli A
J Cancer Res Clin Oncol; 2006 Oct; 132(10):673-83. PubMed ID: 16826403
[TBL] [Abstract][Full Text] [Related]
10. Novel anticancer prodrugs of butyric acid. 2.
Nudelman A; Ruse M; Aviram A; Rabizadeh E; Shaklai M; Zimrah Y; Rephaeli A
J Med Chem; 1992 Feb; 35(4):687-94. PubMed ID: 1542095
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
12. AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines.
Entin-Meer M; Rephaeli A; Yang X; Nudelman A; Nudelman A; Haas-Kogan DA
Cancer Lett; 2007 Aug; 253(2):205-14. PubMed ID: 17346876
[TBL] [Abstract][Full Text] [Related]
13. Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
Nudelman A; Rephaeli A
J Med Chem; 2000 Jul; 43(15):2962-6. PubMed ID: 10956204
[TBL] [Abstract][Full Text] [Related]
14. Comparative antitumor properties in rodents of irreversible inhibitors of L-ornithine decarboxylase, used as such or as prodrugs.
Claverie N; Mamont PS
Cancer Res; 1989 Aug; 49(16):4466-71. PubMed ID: 2501026
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
Gediya LK; Khandelwal A; Patel J; Belosay A; Sabnis G; Mehta J; Purushottamachar P; Njar VC
J Med Chem; 2008 Jul; 51(13):3895-904. PubMed ID: 18543902
[TBL] [Abstract][Full Text] [Related]
16. Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line.
Aviram A; Zimrah Y; Shaklai M; Nudelman A; Rephaeli A
Int J Cancer; 1994 Mar; 56(6):906-9. PubMed ID: 8119779
[TBL] [Abstract][Full Text] [Related]
17. Design of pH responsive clickable prodrugs applied to histone deacetylase inhibitors: a new strategy for anticancer therapy.
Delatouche R; Denis I; Grinda M; El Bahhaj F; Baucher E; Collette F; Héroguez V; Grégoire M; Blanquart C; Bertrand P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):862-72. PubMed ID: 23537575
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of acetylation, proliferation, mitosis, and apoptosis in tumor xenografts following administration of a histone deacetylase inhibitor--a pilot study.
Mitić T; McKay JS
Toxicol Pathol; 2005; 33(7):792-9. PubMed ID: 16392174
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
